Recursion Pharmaceuticals (RXRX) News Today $4.98 +0.07 (+1.43%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$5.07 +0.09 (+1.71%) As of 09:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 AdvancesSeptember 22 at 6:10 PM | finance.yahoo.comRecursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 AdvancesSeptember 21 at 10:31 AM | insidermonkey.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 4,149,346 Shares of Recursion Pharmaceuticals, Inc. $RXRXSeptember 17, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should KnowSeptember 16, 2025 | msn.comGoldman Sachs Group Inc. Has $7.91 Million Holdings in Recursion Pharmaceuticals, Inc. $RXRXSeptember 16, 2025 | marketbeat.comNeedham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8September 15, 2025 | msn.comStock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)September 13, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.7% Higher - Here's What HappenedSeptember 12, 2025 | marketbeat.comRecursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)September 12, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Receives "Buy" Rating from Needham & Company LLCSeptember 12, 2025 | marketbeat.comRecursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLCSeptember 12, 2025 | americanbankingnews.comRecursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Advisors Asset Management Inc.September 10, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comRussell Investments Group Ltd. Has $206,000 Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRXSeptember 4, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comJump Financial LLC Increases Position in Recursion Pharmaceuticals, Inc. $RXRXAugust 29, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 AcquisitionAugust 28, 2025 | insidermonkey.comRecursion to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLCAugust 25, 2025 | marketbeat.comNeedham Maintains Buy Rating on Recursion (RXRX)August 24, 2025 | msn.comThe Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to ExplodeAugust 23, 2025 | fool.comRecursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.August 23, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Caught a Cold This WeekAugust 22, 2025 | fool.comRecursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025August 22, 2025 | finance.yahoo.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of StockAugust 21, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of SharesAugust 21, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's WhyAugust 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 SharesAugust 20, 2025 | insidertrades.comEverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comLPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comRecursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment DataAugust 19, 2025 | seekingalpha.comLiontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)August 18, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.August 18, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical CandidAugust 17, 2025 | insidermonkey.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by BrokeragesAugust 14, 2025 | marketbeat.comRecursion Pharmaceuticals: Two Clinical Readouts In H2'25August 13, 2025 | seekingalpha.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Blair William & Co. ILAugust 12, 2025 | marketbeat.comRecursion Pharmaceuticals’ Earnings Call Highlights Progress and ChallengesAugust 11, 2025 | theglobeandmail.com3 Brilliant Growth Stocks to Buy Now and Hold for the Long TermAugust 10, 2025 | fool.comEquities Analysts Set Expectations for RXRX Q3 EarningsAugust 9, 2025 | marketbeat.comHeadlands Technologies LLC Buys 76,536 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)August 9, 2025 | marketbeat.comIs Recursion Pharmaceuticals (RXRX) Nvidia's Key AI Biotech Stake a Buy Amid Innovation Surge?August 8, 2025 | 247wallst.comBroker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging HigherAugust 6, 2025 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Expectations By $0.06 EPSAugust 6, 2025 | marketbeat.com5RXRX : Recursion Pharmaceuticals Earnings PreviewAugust 6, 2025 | benzinga.comRecursion (RXRX) Q2 Revenue Jumps 33%August 6, 2025 | theglobeandmail.comRecursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?August 6, 2025 | msn.comWhy Recursion Pharmaceuticals Stock Tanked on TuesdayAugust 5, 2025 | fool.comRecursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.com Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Videos RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼1.100.73▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼310▲RXRX Articles Average Week Get the Latest News and Ratings for RXRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Recursion Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Grifols News Today Rhythm Pharmaceuticals News Today Abivax News Today Cytokinetics News Today Legend Biotech News Today Axsome Therapeutics News Today Nuvalent News Today Avidity Biosciences News Today Merus News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
